enrollment in the newly diagnosed unfit aml cohorts of the trial is complete and we continue to follow patients in the trial . as of the data cut-off , 40 newly diagnosed unfit aml patients had been enrolled in the trial and were eligible for the safety analysis . we reported at esh 2019 that sy-1425 in combination with azacitidine had been generally well-tolerated , with no evidence of increased toxicities due to the combination , and that adverse events had been consistent with what has previously been seen with sy-1425 and azacitidine as single agents in aml . across all grades and causalities , the most commonly reported adverse events in these cohorts of the trial were nausea , decreased appetite , constipation , fatigue and peripheral edema , the majority of which were low grade . of the 17 biomarker-positive patients evaluable for response , 13 were rara-positive and four were irf8-positive . we reported at esh 2019 that the aggregate rate of complete response , or cr , and complete 85 response with incomplete blood count recovery , or cri , in each case as defined by revised international working group , or iwg , criteria for aml , as of the data cut-off in rara-positive patients was 62 % and the cr rate was 54 % . the duration of responses in rara-positive patients was up to 344 days , with three of the eight responding patients having responses lasting beyond seven months at the time of the data cut-off . in patients with only the irf8 biomarker , the cr/cri rate was 0 % , supporting our decision to use rara as the sole biomarker for patient selection in sy-1425 clinical trials going forward . most of the initial responses reported were seen at the end of the first treatment cycle . in 22 response-evaluable rara-negative patients , the cr/cri rate was 27 % . single-agent azacitidine has shown response rates of 18-29 % in newly diagnosed unfit aml patients , with initial responses generally occurring after four cycles of treatment in most patients who respond . we expect to report mature data from the newly diagnosed aml cohorts of the trial , as well as potential proof-of-concept data from the relapsed or refractory aml cohort of the trial , in the fourth quarter of 2020. in january 2020 , we dosed the first patient in a phase 1 clinical trial of sy-5609 in patients with select advanced solid tumors , including breast , colorectal , lung and ovarian cancers , and in solid tumors of any histology having retinoblastoma-pathway , or rb pathway , alterations . the primary objectives of this trial are to assess the safety and tolerability of escalating doses of sy-5609 , with the goal of establishing a maximum tolerated dose . additional objectives include assessments of anti-tumor activity , pharmacokinetics , pharmacodynamics and potential predictive biomarkers , including rb pathway alterations . in a future expansion portion of the phase 1 trial , multiple cohorts are planned to further evaluate the safety and anti-tumor activity of sy-5609 as both a single agent and in combination with other therapies . we expect to report initial safety , tolerability , and pharmacokinetic and pharmacodynamic data from the trial in the fourth quarter of 2020. we also expect to report additional dose escalation data , including clinical activity data , in mid-2021 . at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics held in october 2019 , or ena 2019 , we presented preclinical data characterizing the profile of sy-5609 . these data show that sy-5609 is a potent and highly selective cdk7 inhibitor , with at least 13,000-fold greater selectivity for cdk7 over closely related members of the cyclin- dependent kinase family . in addition , we reported at ena 2019 that sy-5609 induced dose-dependent tumor growth inhibition in preclinical models of ovarian and breast cancer , tumor regressions that were sustained after the end of treatment at well-tolerated doses in multiple preclinical models of triple-negative breast , small cell lung , and high-grade serous ovarian cancers . deeper and more sustained responses in these models were associated with the presence of rb pathway alterations . we also reported preclinical data showing the anti-tumor activity of sy-5609 in combination with fulvestrant , a hormonal therapy , in treatment-resistant preclinical models of estrogen receptor-positive breast cancer . we have shown that sy-5609 inhibits cdk7 more potently and selectively than sy-1365 , and that sy-5609 demonstrated greater tumor growth inhibition than sy-1365 in preclinical models in which both agents were studied , including models that were not responsive to sy-1365 . in october 2019 , we announced data from the expansion portion of our phase 1 clinical trial evaluating sy-1365 in multiple solid tumor indications . as of a september 30 , 2019 data snapshot , 68 patients had been treated in the expansion portion of this trial , including 53 across the single-agent cohorts in patients with high-grade serous ovarian cancer , relapsed clear cell ovarian cancer , and solid tumors of any histology available for biopsy , and 15 patients in combination cohorts evaluating sy-1365 in combination with carboplatin , a chemotherapeutic agent , in patients with high-grade serous ovarian cancer and in combination with fulvestrant in patients with treatment-resistant metastatic hormone-receptor positive breast cancer . we initiated the single-agent expansion cohorts at a dose of 80 mg/m 2 twice weekly and the combination cohorts at 53 mg/m 2 once weekly after having observed data from the dose-escalation portion of the trial demonstrating dose-dependent effects on cdk7 occupancy and downstream gene expression changes in blood cells as well as a confirmed partial response in one patient with recurrent clear cell ovarian cancer . story_separator_special_tag 90 stock-based compensation we account for our stock-based compensation awards in accordance with asc 718 , compensation—stock compensation ( “ asc 718 ” ) . asc 718 requires all stock-based payments to employees and directors , including grants of restricted stock units and stock option awards , to be recognized as expense in the consolidated statements of operations based on their grant date fair values . effective january 1 , 2019 , grants of restricted stock units and stock option awards to other service providers , referred to as non-employees , are measured based on the grant-date fair value of the award and expensed in our consolidated statement of operations over the vesting period . through december 31 , 2018 , grants of restricted stock unit and stock option awards to non-employees were required to be recognized as expense in the consolidated statements of operations based on their vesting date fair values . we estimate the fair value of stock options granted using the black-scholes option-pricing model . prior to june 30 , 2016 , we were a private company and , therefore , lack company-specific historical and implied volatility information . as a result , we estimate our expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded stock price . the expected term of our stock options has been determined utilizing the “ simplified ” method for awards that qualify as “ plain-vanilla ” options . through december 31 , 2018 , the expected term of stock options granted to non-employees was equal to the contractual term of the option award . effective january 1 , 2019 , the expected term of stock options to non-employees can be determined using either the contractual term of the option award or the “ simplified ” method . the risk-free interest rate is determined by reference to the u.s. treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award . expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future . we use the value of our common stock to determine the fair value of restricted stock awards . we expense the fair value of our stock-based awards to employees and non-employees on a straight-line basis over the associated service period , which is generally the vesting period . we account for forfeitures as they occur instead of estimating forfeitures at the time of grant . ultimately , the actual expense recognized over the vesting period will be for only those options that vest . compensation expense for discounted purchases under the employee stock purchase plan is measured using the black-scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period . for stock-based awards that contain performance-based milestones , we record stock-based compensation expense in accordance with the accelerated attribution model . management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date . for certain of our performance-based awards , notwithstanding any vesting in accordance with the achievement of performance-based milestones , such awards vest in full on the sixth anniversary of the vesting commencement date . compensation expense for such awards is recognized over the six-year vesting period unless management determines that the achievement of any performance-based milestones is probable , in which case expense is accelerated . we have computed the fair value of stock options at the date of grant using the following weighted-average assumptions : replace_table_token_4_th 91 results of operations comparison of years ended december 31 , 2019 and 2018 the following table summarizes our results of operations for the years ended december 31 , 2019 and 2018 , together with the changes in those items in dollars ( in thousands ) : replace_table_token_5_th revenue for the year ended december 31 , 2019 and 2018 , we recognized approximately $ 2.0 million and $ 2.1 million of revenue , all of which was attributable to our target discovery collaboration with incyte . research and development expense research and development expense increased by approximately $ 8.0 million , or 16 % , from $ 50.2 million for the year ended december 31 , 2018 to $ 58.2 million for the year ended december 31 , 2019. the following table summarizes our research and development expenses for the years ended december 31 , 2019 and 2018 , together with the changes to those items in dollars ( in thousands ) : replace_table_token_6_th the change in research and development expense was primarily attributable to research and development activities associated with advancing our lead clinical and preclinical programs and enhancing our internal capabilities , and included the following : an increase of approximately $ 4.0 million , or 35 % , for increased employee-related expenses , including increased salary and benefits primarily due to our increased headcount ; an increase of approximately $ 1.1 million , or 44 % , for stock-based compensation , also primarily due to our increased headcount ; an increase of approximately $ 1.7 million , or 90 % , consulting , licensing and professional fees increased professional fees in support of our sy-1425 , sy-1365 and sy-5609 clinical trials and our other preclinical programs ; and an increase of approximately $ 1.4 million , or 35 % , in facilities and other expenses primarily due to the rent expense related to the lease for our new headquarters , over which we took possession for accounting purposes in may 2019 . 92 general and administrative expense general and administrative expense increased by approximately $ 5.3

net cash used in operating activities the use of cash in all periods presented resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital . net cash used in operating activities was $ 60.3 million during the year ended december 31 , 2019 , compared to $ 40.3 million during the year ended december 31 , 2018. the increase in cash used in operating activities was primarily due to a $ 13.1 million increase in our net loss from continuing operations and proceeds received upon entry into the incyte target discovery collaboration during the year ended december 31 , 2018 that did not recur in 2019. net cash used in operating activities was $ 40.3 million during the year ended december 31 , 2018 , compared to $ 44.7 million during the year ended december 31 , 2017. the decrease in cash used in operating activities was primarily due to proceeds received upon entry into the incyte target discovery collaboration during the year ended december 31 , 2018. net cash used in investing activities net cash used in investing activities was $ 11.7 million during the year ended december 31 , 2019 , compared to $ 10.6 million during the year ended december 31 , 2018. the increase in cash used in investing activities was primarily due to $ 12.6 million of purchases of property and equipment during the year ended december 31 , 2019 as compared to $ 1.4 million for the year ended december 31 , 2018 due to the buildout of our new corporate headquarters during the year ending december 31 , 2019. this amount was offset by net maturities of marketable securities of $ 0.8 million for the year ended december 31 , 2019 , as compared to net purchases of $ 9.3 million for the year ended december 31 , 2018. net cash used in investing activities was $ 10.6 million during the year ended december 31 , 2018 , compared to $ 15.6 million during the year ended december 31 , 2017. the decrease in cash used in investing activities was primarily due to net


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash used in operating activities the use of cash in all periods presented resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital . net cash used in operating activities was $ 60.3 million during the year ended december 31 , 2019 , compared to $ 40.3 million during the year ended december 31 , 2018. the increase in cash used in operating activities was primarily due to a $ 13.1 million increase in our net loss from continuing operations and proceeds received upon entry into the incyte target discovery collaboration during the year ended december 31 , 2018 that did not recur in 2019. net cash used in operating activities was $ 40.3 million during the year ended december 31 , 2018 , compared to $ 44.7 million during the year ended december 31 , 2017. the decrease in cash used in operating activities was primarily due to proceeds received upon entry into the incyte target discovery collaboration during the year ended december 31 , 2018. net cash used in investing activities net cash used in investing activities was $ 11.7 million during the year ended december 31 , 2019 , compared to $ 10.6 million during the year ended december 31 , 2018. the increase in cash used in investing activities was primarily due to $ 12.6 million of purchases of property and equipment during the year ended december 31 , 2019 as compared to $ 1.4 million for the year ended december 31 , 2018 due to the buildout of our new corporate headquarters during the year ending december 31 , 2019. this amount was offset by net maturities of marketable securities of $ 0.8 million for the year ended december 31 , 2019 , as compared to net purchases of $ 9.3 million for the year ended december 31 , 2018. net cash used in investing activities was $ 10.6 million during the year ended december 31 , 2018 , compared to $ 15.6 million during the year ended december 31 , 2017. the decrease in cash used in investing activities was primarily due to net
```    
 Suspicious Activity Report : enrollment in the newly diagnosed unfit aml cohorts of the trial is complete and we continue to follow patients in the trial . as of the data cut-off , 40 newly diagnosed unfit aml patients had been enrolled in the trial and were eligible for the safety analysis . we reported at esh 2019 that sy-1425 in combination with azacitidine had been generally well-tolerated , with no evidence of increased toxicities due to the combination , and that adverse events had been consistent with what has previously been seen with sy-1425 and azacitidine as single agents in aml . across all grades and causalities , the most commonly reported adverse events in these cohorts of the trial were nausea , decreased appetite , constipation , fatigue and peripheral edema , the majority of which were low grade . of the 17 biomarker-positive patients evaluable for response , 13 were rara-positive and four were irf8-positive . we reported at esh 2019 that the aggregate rate of complete response , or cr , and complete 85 response with incomplete blood count recovery , or cri , in each case as defined by revised international working group , or iwg , criteria for aml , as of the data cut-off in rara-positive patients was 62 % and the cr rate was 54 % . the duration of responses in rara-positive patients was up to 344 days , with three of the eight responding patients having responses lasting beyond seven months at the time of the data cut-off . in patients with only the irf8 biomarker , the cr/cri rate was 0 % , supporting our decision to use rara as the sole biomarker for patient selection in sy-1425 clinical trials going forward . most of the initial responses reported were seen at the end of the first treatment cycle . in 22 response-evaluable rara-negative patients , the cr/cri rate was 27 % . single-agent azacitidine has shown response rates of 18-29 % in newly diagnosed unfit aml patients , with initial responses generally occurring after four cycles of treatment in most patients who respond . we expect to report mature data from the newly diagnosed aml cohorts of the trial , as well as potential proof-of-concept data from the relapsed or refractory aml cohort of the trial , in the fourth quarter of 2020. in january 2020 , we dosed the first patient in a phase 1 clinical trial of sy-5609 in patients with select advanced solid tumors , including breast , colorectal , lung and ovarian cancers , and in solid tumors of any histology having retinoblastoma-pathway , or rb pathway , alterations . the primary objectives of this trial are to assess the safety and tolerability of escalating doses of sy-5609 , with the goal of establishing a maximum tolerated dose . additional objectives include assessments of anti-tumor activity , pharmacokinetics , pharmacodynamics and potential predictive biomarkers , including rb pathway alterations . in a future expansion portion of the phase 1 trial , multiple cohorts are planned to further evaluate the safety and anti-tumor activity of sy-5609 as both a single agent and in combination with other therapies . we expect to report initial safety , tolerability , and pharmacokinetic and pharmacodynamic data from the trial in the fourth quarter of 2020. we also expect to report additional dose escalation data , including clinical activity data , in mid-2021 . at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics held in october 2019 , or ena 2019 , we presented preclinical data characterizing the profile of sy-5609 . these data show that sy-5609 is a potent and highly selective cdk7 inhibitor , with at least 13,000-fold greater selectivity for cdk7 over closely related members of the cyclin- dependent kinase family . in addition , we reported at ena 2019 that sy-5609 induced dose-dependent tumor growth inhibition in preclinical models of ovarian and breast cancer , tumor regressions that were sustained after the end of treatment at well-tolerated doses in multiple preclinical models of triple-negative breast , small cell lung , and high-grade serous ovarian cancers . deeper and more sustained responses in these models were associated with the presence of rb pathway alterations . we also reported preclinical data showing the anti-tumor activity of sy-5609 in combination with fulvestrant , a hormonal therapy , in treatment-resistant preclinical models of estrogen receptor-positive breast cancer . we have shown that sy-5609 inhibits cdk7 more potently and selectively than sy-1365 , and that sy-5609 demonstrated greater tumor growth inhibition than sy-1365 in preclinical models in which both agents were studied , including models that were not responsive to sy-1365 . in october 2019 , we announced data from the expansion portion of our phase 1 clinical trial evaluating sy-1365 in multiple solid tumor indications . as of a september 30 , 2019 data snapshot , 68 patients had been treated in the expansion portion of this trial , including 53 across the single-agent cohorts in patients with high-grade serous ovarian cancer , relapsed clear cell ovarian cancer , and solid tumors of any histology available for biopsy , and 15 patients in combination cohorts evaluating sy-1365 in combination with carboplatin , a chemotherapeutic agent , in patients with high-grade serous ovarian cancer and in combination with fulvestrant in patients with treatment-resistant metastatic hormone-receptor positive breast cancer . we initiated the single-agent expansion cohorts at a dose of 80 mg/m 2 twice weekly and the combination cohorts at 53 mg/m 2 once weekly after having observed data from the dose-escalation portion of the trial demonstrating dose-dependent effects on cdk7 occupancy and downstream gene expression changes in blood cells as well as a confirmed partial response in one patient with recurrent clear cell ovarian cancer . story_separator_special_tag 90 stock-based compensation we account for our stock-based compensation awards in accordance with asc 718 , compensation—stock compensation ( “ asc 718 ” ) . asc 718 requires all stock-based payments to employees and directors , including grants of restricted stock units and stock option awards , to be recognized as expense in the consolidated statements of operations based on their grant date fair values . effective january 1 , 2019 , grants of restricted stock units and stock option awards to other service providers , referred to as non-employees , are measured based on the grant-date fair value of the award and expensed in our consolidated statement of operations over the vesting period . through december 31 , 2018 , grants of restricted stock unit and stock option awards to non-employees were required to be recognized as expense in the consolidated statements of operations based on their vesting date fair values . we estimate the fair value of stock options granted using the black-scholes option-pricing model . prior to june 30 , 2016 , we were a private company and , therefore , lack company-specific historical and implied volatility information . as a result , we estimate our expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded stock price . the expected term of our stock options has been determined utilizing the “ simplified ” method for awards that qualify as “ plain-vanilla ” options . through december 31 , 2018 , the expected term of stock options granted to non-employees was equal to the contractual term of the option award . effective january 1 , 2019 , the expected term of stock options to non-employees can be determined using either the contractual term of the option award or the “ simplified ” method . the risk-free interest rate is determined by reference to the u.s. treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award . expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future . we use the value of our common stock to determine the fair value of restricted stock awards . we expense the fair value of our stock-based awards to employees and non-employees on a straight-line basis over the associated service period , which is generally the vesting period . we account for forfeitures as they occur instead of estimating forfeitures at the time of grant . ultimately , the actual expense recognized over the vesting period will be for only those options that vest . compensation expense for discounted purchases under the employee stock purchase plan is measured using the black-scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period . for stock-based awards that contain performance-based milestones , we record stock-based compensation expense in accordance with the accelerated attribution model . management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date . for certain of our performance-based awards , notwithstanding any vesting in accordance with the achievement of performance-based milestones , such awards vest in full on the sixth anniversary of the vesting commencement date . compensation expense for such awards is recognized over the six-year vesting period unless management determines that the achievement of any performance-based milestones is probable , in which case expense is accelerated . we have computed the fair value of stock options at the date of grant using the following weighted-average assumptions : replace_table_token_4_th 91 results of operations comparison of years ended december 31 , 2019 and 2018 the following table summarizes our results of operations for the years ended december 31 , 2019 and 2018 , together with the changes in those items in dollars ( in thousands ) : replace_table_token_5_th revenue for the year ended december 31 , 2019 and 2018 , we recognized approximately $ 2.0 million and $ 2.1 million of revenue , all of which was attributable to our target discovery collaboration with incyte . research and development expense research and development expense increased by approximately $ 8.0 million , or 16 % , from $ 50.2 million for the year ended december 31 , 2018 to $ 58.2 million for the year ended december 31 , 2019. the following table summarizes our research and development expenses for the years ended december 31 , 2019 and 2018 , together with the changes to those items in dollars ( in thousands ) : replace_table_token_6_th the change in research and development expense was primarily attributable to research and development activities associated with advancing our lead clinical and preclinical programs and enhancing our internal capabilities , and included the following : an increase of approximately $ 4.0 million , or 35 % , for increased employee-related expenses , including increased salary and benefits primarily due to our increased headcount ; an increase of approximately $ 1.1 million , or 44 % , for stock-based compensation , also primarily due to our increased headcount ; an increase of approximately $ 1.7 million , or 90 % , consulting , licensing and professional fees increased professional fees in support of our sy-1425 , sy-1365 and sy-5609 clinical trials and our other preclinical programs ; and an increase of approximately $ 1.4 million , or 35 % , in facilities and other expenses primarily due to the rent expense related to the lease for our new headquarters , over which we took possession for accounting purposes in may 2019 . 92 general and administrative expense general and administrative expense increased by approximately $ 5.3

